Posted by Michael Wonder on 13 Jul 2022
Biosimilar uptake accelerates in US—and so do the savings
13 July 2022 - Amgen's early view said health care savings from the use of these biologic therapies climbed to $3 billion in the second quarter of 2022, for total of $18 billion over the past 6 years.
Use of biosimilars by US physicians is picking up steam, and the marketplace “is poised to growth” in both approvals and uptake after hiccups caused in part by the pandemic, according to a recent industry overview from Amgen.
